SymbolXGN
NameEXAGEN INC.
SectorHEALTH CARE
RegionNorth America
IndustryMedical Specialities
Address1261 LIBERTY WAY,SUITE C, VISTA, California, 92081, United States
Telephone+1 760 560-1501
Fax
Email
Websitehttps://www.exagen.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001274737
Description

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Additional info from NASDAQ:
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

2026-08-24 19:54

New Form 4/A - EXAGEN INC. <b>Filed:</b> 2026-08-24 <b>AccNo:</b> 0001289625-26-000005 <b>Size:</b> 6 KB

Read more
2026-08-19 22:57

Director Robertson Bruce C 🟢 acquired 37.5K shares (1 derivative) of EXAGEN INC. (XGN) at $4.31 Transaction Date: Jun 09, 2026 | Filing ID: 000056

Read more
2026-08-19 22:57

Director Kim Paul 🟢 acquired 37.5K shares (1 derivative) of EXAGEN INC. (XGN) at $4.31 Transaction Date: Jun 09, 2026 | Filing ID: 000054

Read more
2026-08-04 12:00

Exagen Inc. Reports Second Quarter 2026 Financial Results

Read more
2026-07-28 13:00

Exagen Inc. to Participate in Upcoming Investor Conference

Read more
2026-07-21 13:00

Exagen to Announce Second Quarter Financial Results on August 4, 2026

Read more
2026-06-22 17:38

Director KAHN SCOTT D 🟢 acquired 37.5K shares (1 derivative) of EXAGEN INC. (XGN) at $4.31 Transaction Date: Jun 09, 2026 | Filing ID: 000043

Read more
2026-06-22 17:11

Director McKhann Chas 🟢 acquired 37.5K shares (1 derivative) of EXAGEN INC. (XGN) at $4.31 Transaction Date: Jun 09, 2026 | Filing ID: 000038

Read more
2026-06-22 17:00

Director Stokes Frank 🟢 acquired 37.5K shares (1 derivative) of EXAGEN INC. (XGN) at $4.31 Transaction Date: Jun 09, 2026 | Filing ID: 000007

Read more
2026-06-09 20:14

(99% Neutral) EXAGEN INC. (XGN) Announces Regulatory Update

Read more